On Nov. 2, 2018, the U.S. Food and Drug Administration announced they had approved AcelRx Pharmaceuticals Inc’s opioid-based pain treatment, a fast-acting pill.

The treatment is approved for moderate-to-severe pain in medically supervised settings such as emergencies and for use in post-operative patients.

The approval comes a year after the initial marketing application for the drug, Dsuvia, was rejected by the agency, which sought additional safety data and certain changes to ensure that the drug was administered properly.